Spero Therapeutics (NASDAQ:SPRO) Earns Sell (D-) Rating from Weiss Ratings

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “sell (d-)” rating restated by research analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Separately, Zacks Research lowered shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 13th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.00.

Spero Therapeutics Stock Performance

NASDAQ SPRO opened at $2.21 on Friday. The firm has a market cap of $124.38 million, a PE ratio of -2.26 and a beta of 1.47. Spero Therapeutics has a one year low of $0.51 and a one year high of $3.22. The firm’s fifty day moving average is $2.06 and its two-hundred day moving average is $1.93.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.35. The company had revenue of $14.19 million for the quarter, compared to analyst estimates of $11.00 million. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. Research analysts predict that Spero Therapeutics will post -1.2 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Assenagon Asset Management S.A. acquired a new position in shares of Spero Therapeutics during the third quarter worth about $70,000. Stonepine Capital Management LLC acquired a new position in shares of Spero Therapeutics during the second quarter worth about $455,000. Invesco Ltd. acquired a new position in Spero Therapeutics during the second quarter worth about $43,000. Quadrature Capital Ltd acquired a new position in Spero Therapeutics during the second quarter worth about $90,000. Finally, XTX Topco Ltd acquired a new position in Spero Therapeutics during the second quarter worth about $100,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.